- Home
- YMAB
as 11-15-2024 4:00pm EST
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 631.1M | IPO Year: | 2018 |
| Target Price: | $21.38 | AVG Volume (30 days): | 268.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.17 - $20.90 | Next Earning Date: | 11-08-2024 |
| Revenue: | $84,553,000 | Revenue Growth: | -8.99% |
| Revenue Growth (this year): | 10.24% | Revenue Growth (next year): | 20.21% |
Stock Insider Trading Activity of Y-mAbs Therapeutics Inc. (YMAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gad Thomas | YMAB | CHIEF BUSINESS OFFICER | Sep 13 '24 | Sell | $13.22 | 95,000 | $1,264,650.00 | 97,681 | |
| Lund-Hansen Torben | YMAB | SVP & CHIEF TECHNICAL OFFICER | Aug 28 '24 | Sell | $15.37 | 50,000 | $768,500.00 | 35,600 | |
| Wilms Joris | YMAB | SVP & CHIEF OPERATING OFFICER | Aug 26 '24 | Sell | $14.69 | 5,000 | $73,450.00 | 30,600 |
Latest Y-mAbs Therapeutics Inc. News
YMAB Breaking Stock News: Dive into YMAB Ticker-Specific Updates for Smart Investing
GuruFocus.com
8 days ago
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
Zacks
9 days ago
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
9 days ago
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
GuruFocus.com
10 days ago
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings
Zacks
12 days ago
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
GlobeNewswire
13 days ago
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
Zacks
16 days ago
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
GlobeNewswire
23 days ago
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
Compare YMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "YMAB Y-mAbs Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.